Table of Contents
Chapter 1. Global Heart Failure Therapeutics Market Executive Summary
1.1. Global Heart Failure Therapeutics Market Size & Forecast (2024-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Treatment
1.3.2. By Type
1.3.3. By Stage
1.3.4. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Heart Failure Therapeutics Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer's Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Heart Failure Therapeutics Market Dynamics
3.1. Market Drivers
3.1.1. Aging population and rising prevalence of heart failure
3.1.2. Advancements in medical technology and treatment options
3.1.3. Increased healthcare expenditure in developing economies
3.2. Market Challenges
3.2.1. Regulatory complexities and reimbursement issues
3.2.2. High R&D costs and therapeutic solution expenses
3.2.3. Underdiagnosis and unawareness in certain regions
3.3. Market Opportunities
3.3.1. Development of gene and stem cell therapies
3.3.2. Integration of AI and machine learning in diagnostics
3.3.3. Growth in remote patient monitoring and digital health tools
Chapter 4. Global Heart Failure Therapeutics Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Heart Failure Therapeutics Market Size & Forecasts by Treatment 2024-2032
5.1. Segment Dashboard
5.2. Global Heart Failure Therapeutics Market: Treatment Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Medical Devices
5.2.1.1. Bi-level positive air pressure device
5.2.1.2. Biventricular Pacemaker
5.2.1.3. Continuous Positive Air Pressure Device
5.2.1.4. Heart Pumps
5.2.1.5. Implantable Cardioverter-Defibrillators
5.2.1.6. Implantable Left Ventricular Assist Device
5.2.2. Medicines
5.2.2.1. Angiotensin II Receptor Blockers
5.2.2.2. Anticoagulant Medicines
5.2.2.3. Antiplatelet Medicines
5.2.2.4. Blood Pressure Maintaining Agents
5.2.2.5. Diuretics
5.2.2.6. Nitrates
5.2.2.7. Statins
5.2.3. Surgery
5.2.3.1. Cardiac Resynchronization
5.2.3.2. Coronary Artery Bypass Grafting
5.2.3.3. Coronary Revascularization
5.2.3.4. Heart Transplant
5.2.3.5. Heart Valve Replacement
Chapter 6. Global Heart Failure Therapeutics Market Size & Forecasts by Type 2024-2032
6.1. Segment Dashboard
6.2. Global Heart Failure Therapeutics Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Diagnosis
6.2.2. Prognosis
Chapter 7. Global Heart Failure Therapeutics Market Size & Forecasts by Stage 2024-2032
7.1. Segment Dashboard
7.2. Global Heart Failure Therapeutics Market: Stage Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Stage A
7.2.2. Stage B
7.2.3. Stage C
7.2.4. Stage D
Chapter 8. Global Heart Failure Therapeutics Market Size & Forecasts by End User 2024-2032
8.1. Segment Dashboard
8.2. Global Heart Failure Therapeutics Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Clinic
8.2.2. Hospital
8.2.3. Medical Research Organization
Chapter 9. Global Heart Failure Therapeutics Market Size & Forecasts by Region 2024-2032
9.1. North America Heart Failure Therapeutics Market
9.1.1. U.S. Heart Failure Therapeutics Market
9.1.1.1. Treatment breakdown size & forecasts, 2024-2032
9.1.1.2. Type breakdown size & forecasts, 2024-2032
9.1.1.3. Stage breakdown size & forecasts, 2024-2032
9.1.1.4. End User breakdown size & forecasts, 2024-2032
9.1.2. Canada Heart Failure Therapeutics Market
9.1.2.1. Treatment breakdown size & forecasts, 2024-2032
9.1.2.2. Type breakdown size & forecasts, 2024-2032
9.1.2.3. Stage breakdown size & forecasts, 2024-2032
9.1.2.4. End User breakdown size & forecasts, 2024-2032
9.2. Europe Heart Failure Therapeutics Market
9.2.1. U.K. Heart Failure Therapeutics Market
9.2.1.1. Treatment breakdown size & forecasts, 2024-2032
9.2.1.2. Type breakdown size & forecasts, 2024-2032
9.2.1.3. Stage breakdown size & forecasts, 2024-2032
9.2.1.4. End User breakdown size & forecasts, 2024-2032
9.2.2. Germany Heart Failure Therapeutics Market
9.2.2.1. Treatment breakdown size & forecasts, 2024-2032
9.2.2.2. Type breakdown size & forecasts, 2024-2032
9.2.2.3. Stage breakdown size & forecasts, 2024-2032
9.2.2.4. End User breakdown size & forecasts, 2024-2032
9.2.3. France Heart Failure Therapeutics Market
9.2.3.1. Treatment breakdown size & forecasts, 2024-2032
9.2.3.2. Type breakdown size & forecasts, 2024-2032
9.2.3.3. Stage breakdown size & forecasts, 2024-2032
9.2.3.4. End User breakdown size & forecasts, 2024-2032
9.2.4. Spain Heart Failure Therapeutics Market
9.2.4.1. Treatment breakdown size & forecasts, 2024-2032
9.2.4.2. Type breakdown size & forecasts, 2024-2032
9.2.4.3. Stage breakdown size & forecasts, 2024-2032
9.2.4.4. End User breakdown size & forecasts, 2024-2032
9.2.5. Italy Heart Failure Therapeutics Market
9.2.5.1. Treatment breakdown size & forecasts, 2024-2032
9.2.5.2. Type breakdown size & forecasts, 2024-2032
9.2.5.3. Stage breakdown size & forecasts, 2024-2032
9.2.5.4. End User breakdown size & forecasts, 2024-2032
9.2.6. Rest of Europe Heart Failure Therapeutics Market
9.2.6.1. Treatment breakdown size & forecasts, 2024-2032
9.2.6.2. Type breakdown size & forecasts, 2024-2032
9.2.6.3. Stage breakdown size & forecasts, 2024-2032
9.2.6.4. End User breakdown size & forecasts, 2024-2032
9.3. Asia-Pacific Heart Failure Therapeutics Market
9.3.1. China Heart Failure Therapeutics Market
9.3.1.1. Treatment breakdown size & forecasts, 2024-2032
9.3.1.2. Type breakdown size & forecasts, 2024-2032
9.3.1.3. Stage breakdown size & forecasts, 2024-2032
9.3.1.4. End User breakdown size & forecasts, 2024-2032
9.3.2. India Heart Failure Therapeutics Market
9.3.2.1. Treatment breakdown size & forecasts, 2024-2032
9.3.2.2. Type breakdown size & forecasts, 2024-2032
9.3.2.3. Stage breakdown size & forecasts, 2024-2032
9.3.2.4. End User breakdown size & forecasts, 2024-2032
9.3.3. Japan Heart Failure Therapeutics Market
9.3.3.1. Treatment breakdown size & forecasts, 2024-2032
9.3.3.2. Type breakdown size & forecasts, 2024-2032
9.3.3.3. Stage breakdown size & forecasts, 2024-2032
9.3.3.4. End User breakdown size & forecasts, 2024-2032
9.3.4. Australia Heart Failure Therapeutics Market
9.3.4.1. Treatment breakdown size & forecasts, 2024-2032
9.3.4.2. Type breakdown size & forecasts, 2024-2032
9.3.4.3. Stage breakdown size & forecasts, 2024-2032
9.3.4.4. End User breakdown size & forecasts, 2024-2032
9.3.5. South Korea Heart Failure Therapeutics Market
9.3.5.1. Treatment breakdown size & forecasts, 2024-2032
9.3.5.2. Type breakdown size & forecasts, 2024-2032
9.3.5.3. Stage breakdown size & forecasts, 2024-2032
9.3.5.4. End User breakdown size & forecasts, 2024-2032
9.3.6. Rest of Asia Pacific Heart Failure Therapeutics Market
9.3.6.1. Treatment breakdown size & forecasts, 2024-2032
9.3.6.2. Type breakdown size & forecasts, 2024-2032
9.3.6.3. Stage breakdown size & forecasts, 2024-2032
9.3.6.4. End User breakdown size & forecasts, 2024-2032
9.4. Latin America Heart Failure Therapeutics Market
9.4.1. Brazil Heart Failure Therapeutics Market
9.4.1.1. Treatment breakdown size & forecasts, 2024-2032
9.4.1.2. Type breakdown size & forecasts, 2024-2032
9.4.1.3. Stage breakdown size & forecasts, 2024-2032
9.4.1.4. End User breakdown size & forecasts, 2024-2032
9.4.2. Mexico Heart Failure Therapeutics Market
9.4.2.1. Treatment breakdown size & forecasts, 2024-2032
9.4.2.2. Type breakdown size & forecasts, 2024-2032
9.4.2.3. Stage breakdown size & forecasts, 2024-2032
9.4.2.4. End User breakdown size & forecasts, 2024-2032
9.4.3. Rest of Latin America Heart Failure Therapeutics Market
9.4.3.1. Treatment breakdown size & forecasts, 2024-2032
9.4.3.2. Type breakdown size & forecasts, 2024-2032
9.4.3.3. Stage breakdown size & forecasts, 2024-2032
9.4.3.4. End User breakdown size & forecasts, 2024-2032
9.5. Middle East & Africa Heart Failure Therapeutics Market
9.5.1. Saudi Arabia Heart Failure Therapeutics Market
9.5.1.1. Treatment breakdown size & forecasts, 2024-2032
9.5.1.2. Type breakdown size & forecasts, 2024-2032
9.5.1.3. Stage breakdown size & forecasts, 2024-2032
9.5.1.4. End User breakdown size & forecasts, 2024-2032
9.5.2. South Africa Heart Failure Therapeutics Market
9.5.2.1. Treatment breakdown size & forecasts, 2024-2032
9.5.2.2. Type breakdown size & forecasts, 2024-2032
9.5.2.3. Stage breakdown size & forecasts, 2024-2032
9.5.2.4. End User breakdown size & forecasts, 2024-2032
9.5.3. Rest of Middle East & Africa Heart Failure Therapeutics Market
9.5.3.1. Treatment breakdown size & forecasts, 2024-2032
9.5.3.2. Type breakdown size & forecasts, 2024-2032
9.5.3.3. Stage breakdown size & forecasts, 2024-2032
9.5.3.4. End User breakdown size & forecasts, 2024-2032
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. Abbott Laboratories
10.1.2. ABIOMED, Inc.
10.1.3. Amgen Inc.
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Alembic Pharmaceuticals Limited
10.3.2. AstraZeneca PLC
10.3.3. Bayer AG
10.3.4. Beckman Coulter, Inc.
10.3.5. Berlin Heart GmbH
10.3.6. Biosensors International Group, Ltd.
10.3.7. Biotronik SE & Co. KG
10.3.8. Boston Scientific Corporation
10.3.9. Bristol-Myers Squibb Company
10.3.10. Cardiol Therapeutics Inc.
10.3.11. Cipla Limited
10.3.12. Dr. Reddy's Laboratories Limited
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes